# Stocks Gone Wild: October's Short-Squeeze Picks!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-10-03T23:42:02.123Z
Source: https://newsyai.com/edition/e97bf743-e638-44c3-a521-c5e1ebeaf10e
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Wall Street's Fresh Holy Trinity of "WTF Is This Stock Smoking?" – October 3, 2026 Edition**[[1]](https://tapeboard.com/short-squeeze-stocks)

Back at it, you beautiful degenerates. Markets remain a glorious shitshow—AI hype juicing the Nasdaq while the Dow sits there like a bored hooker and crude oil bounces around like a meth-fueled pinball. I scoured the latest short-interest data (Sep 15/25 settlement vibes dominating, with fresh scans) for three *brand-new* names where the bears are piled on like it's a clearance sale on doom, and the bulls are yelling "squeeze this, motherfucker." No repeats of the usual suspects like VG/BROS/BEAM/XPOF/KPTI/PCT/RXRX/etc.—just fresh chaos with notable short pressure and volatility screaming "prove me wrong, bitch." Here's the latest holy trinity of pure, unfiltered "who the fuck knows?"

### 1. SMR (NuScale Power): The Small Modular Reactor Nuclear Hustle
**The Bull Case (We're the Kings of Clean, Scalable Power—AI Data Centers and Global Demand to the Moon):**  
Bulls are hyped on NuScale's first-mover regulatory edge in small modular reactors (SMRs), perfect for powering insatiable AI data centers, long-term contracts in the works (RoPower vibes), and massive tailwinds from energy security, decarbonization, and hyperscaler power hunger. Shorts are aggressive (notable pressure in scans), but any binding PPAs, construction starts, or "finally monetizing the nuclear renaissance" narrative could trigger a violent short squeeze. "We've got the approvals and the tech—watch the modules deploy and shorts get fissioned" is the cope. Expansion? Margin leverage? Shorts left choking on the steam.[[2]](https://seekingalpha.com/article/4951307-nuscale-power-stock-rising-risks-profitability-remains-uncertain-rating-downgrade)

**The Bear Case (Delays, Dilution, and an Earnings Desert in a Litigious Jungle):**  
Reality check: Repeated project delays (RoPower, ENTRA1 drama), massive cash burn with near-zero near-term revenue, heavy dilution risk via ATM offerings, execution hurdles on first-of-a-kind builds, and macro sensitivity to energy prices or recessions. High skepticism reflects the market's "yeah, right" on timely commercialization and balance sheet health. One more setback, ruling, or funding crunch and it's dilution city or worse. NuScale? More like "nu-scale value destruction."[[3]](https://trendmatrix.com/stocks/SMR)

**My First-Principles Breakdown:**  
Strip it down: SMR tech wins on modular scalability, regulatory moat, and exploding demand for reliable baseload power—not just hype. NuScale has the approvals and pipeline optionality, but "dominance" assumes surviving multi-year construction timelines, cost overruns, customer concentration, and commodity/energy cycles. Shorts correctly price in the binary execution and funding risks; bulls correctly price in the asymmetric upside if AI power demand stays nuclear-hot. High-vol energy lottery ticket—entertaining as hell, size accordingly or cry into your electricity bill later.

### 2. VKTX (Viking Therapeutics): The Weight-Loss Drug Cult
**The Bull Case (We're Cracking the Obesity Code—Pipeline Catalysts and Dual-Form Glory to the Moon):**  
Bulls are pumped on Viking's dual GLP-1/GIP agonist VK2735 (injectable and oral paths), strong Phase 2/maintenance data showing solid weight loss and durability, massive addressable market tailwinds from the obesity epidemic, and potential partnerships or buyout vibes. Shorts are stacked (notable in biotech scans), but any Phase 3 beats, oral data, or "finally competing with Lilly/Novo" narrative could spark a squeeze. "We've got the science edge and the unmet need—watch the approvals flow and shorts get slimmed down" is the rally cry. Data readouts? Commercial traction? Shorts left in the dust.[[4]](https://contextwindowfinance.substack.com/p/vktx-the-good-outcome-has-two-prices)

**The Bear Case (Cash-Burning Biotech with Big Pharma Breathing Down Its Neck):**  
Reality bites: Ongoing cash burn and dilution risk (recent equity/convertible raises spooking the market), intense competition from established players with deeper pockets and proven supply chains, uncertain long-term efficacy/safety in larger trials, and a valuation that bakes in perfection. High shorts reflect the market's "yeah, right" on execution in a crowded, binary field. One missed endpoint, regulatory setback, or funding crunch and it's back to square one or worse. Viking? More like "viking me up, Scotty—out of this stock."[[5]](https://www.tipranks.com/news/weekend-updates/viking-therapeutics-slides-as-cash-raise-spooks-wall-street)

**My First-Principles Breakdown:**  
Fundamentally, obesity therapeutics win on efficacy, tolerability, dosing convenience (oral edge), and scalable manufacturing—not just early promise. VKTX has differentiated mechanisms and optionality across formulations, but "blockbuster status" requires surviving deeper-pocketed rivals, proving durable real-world value, and navigating capital markets without excessive dilution. Shorts flag the binary clinical/financial risks; bulls flag the asymmetric upside if data clicks and the market stays hungry. High-risk biotech bet with squeeze lottery potential—trade the catalysts, not your retirement.

### 3. FLNC (Fluence Energy): The Battery Storage Grid Play
**The Bull Case (We're the Kings of Flexible Power—AI Data Centers and Renewables Integration to the Moon):**  
Bulls hype Fluence's energy storage systems for grid stability amid AI-driven power demand spikes, strong backlog and hyperscaler MSAs, domestic supply chain advantages (IRA credits, U.S. manufacturing), and tailwinds from the energy transition. Shorts are piled on (elevated in scans amid volatility), but any order conversions, margin recovery, or "finally delivering on the backlog" news could spark a squeeze. "We've got the tech and the pipeline—watch the deployments flow and shorts get discharged" is the mantra. Margin expansion? Software/services traction? Shorts left wired and wrong.[[6]](https://businessquant.com/stocks/flnc/)

**The Bear Case (Execution Nightmare and Guidance Cliff in a Supply-Chain Jungle):**  
Reality check: Repeated guidance cuts from production delays (Houston facility woes, international hiccups), thin or negative margins, working capital strain, competition from bigger players, and macro sensitivity to project financing or recessions. High shorts reflect the market's "yeah, right" on sustainable execution and path to profitability. One more delay, customer pushback, or cash crunch and it's dilution or worse. Fluence? More like "flu-ence into value destruction."[[7]](https://seekingalpha.com/article/4947332-fluence-energy-sell-on-persistent-execution-and-supply-chain-issues)

**My First-Principles Breakdown:**  
Energy storage wins on rapid response to variable demand, integration with renewables/AI loads, supply chain resilience, and contracted backlogs—not just hype. FLNC has the positioning and domestic edge, but "scaling to dominance" assumes surviving manufacturing ramps, margin pressure, customer concentration, and cycles where capex gets slashed. Shorts correctly price in the operational and financial risks; bulls correctly price in the asymmetric upside if AI power needs stay insatiable. High-vol industrial bet—entertaining as hell, size accordingly or cry into your power bill later.

**Bottom Line (No Crystal Ball, Just Brutal Logic):**  
These three capture the current divided vibe: nuclear SMR infrastructure bet, obesity drug growth gamble, and battery storage execution story. The common thread? Sky-high skepticism via shorts and volatility, but real catalysts that could flip the script. Markets adore punishing uncertainty—and these names are marinated in it. Laugh at the chaos, size positions like your rent depends on it (or don't), and remember: this is entertainment with numbers. Your move, degenerates.

**Sources for the terminally curious (verify this shit yourself):** Recent short-interest trackers and screens (e.g., Tapeboard, FindMyMoat, Benzinga, MarketBeat, Seeking Alpha) highlighting elevated levels and squeeze potential in SMR, VKTX, and FLNC; analyst commentary on sector debates. Always do your own digging—these are snapshots of a deranged market. Trade responsibly, or at least don't cry when it goes tits up.
